These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis. Cohen OC; Sharpley F; Gilbertson JA; Wechalekar AD; Sachchithanantham S; Mahmood S; Whelan CJ; Martinez-Naharro A; Fontana M; Lachmann HJ; Hawkins PN; Gillmore JD Eur J Haematol; 2020 Sep; 105(3):352-356. PubMed ID: 32495369 [TBL] [Abstract][Full Text] [Related]
10. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
11. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy]. Sekijima Y Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679 [TBL] [Abstract][Full Text] [Related]
12. Neuromuscular amyloidosis: Unmasking the master of disguise. Pinto MV; Dyck PJB; Liewluck T Muscle Nerve; 2021 Jul; 64(1):23-36. PubMed ID: 33458861 [TBL] [Abstract][Full Text] [Related]
13. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage. Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. Brownrigg J; Lorenzini M; Lumley M; Elliott P ESC Heart Fail; 2019 Oct; 6(5):1041-1051. PubMed ID: 31487121 [TBL] [Abstract][Full Text] [Related]
15. [Cardiac amyloidosis: State of art in 2022]. Oghina S; Delbarre MA; Poullot E; Belhadj K; Fanen P; Damy T Rev Med Interne; 2022 Sep; 43(9):537-544. PubMed ID: 35870985 [TBL] [Abstract][Full Text] [Related]